Intelligent Bio Solutions Inc. is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its segment includes Commercially available Intelligent Fingerprinting Products and Development Stage Biosensor Platform Technology. Its product portfolio includes Intelligent Fingerprinting Platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader, and a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Biosensor Platform is designed to detect multiple biological analytes by substituting the top enzyme layer of the biosensor to suit each analyte and to develop a range of Point of Care Tests, including the modalities of clinical chemistry, immunology, tumor markers, allergens, and endocrinology.
BörsenkürzelINBS
Name des UnternehmensIntelligent Bio Solutions Inc
IPO-datumDec 23, 2020
CEOMr. Harry Simeonidis
Anzahl der mitarbeiter13
WertpapierartOrdinary Share
GeschäftsjahresendeDec 23
Addresse135 W 41St St,
StadtNEW YORK
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl10036
Telefon16467905756
Websitehttps://ibs.inc/
BörsenkürzelINBS
IPO-datumDec 23, 2020
CEOMr. Harry Simeonidis
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten